de Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020–1032 (2022).
Mayer, E. A., Nance, K. & Chen, S. The gut-brain axis. Annu. Rev. Med. 73, 439–453 (2022).
Article CAS PubMed Google Scholar
Tilg, H., Adolph, T. E. & Trauner, M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 34, 1700–1718 (2022).
Article CAS PubMed Google Scholar
Silveira, M. A. D. et al. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer 8, 583–597 (2022).
Article CAS PubMed PubMed Central Google Scholar
Liu, L., Huh, J. R. & Shah, K. Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine 77, 103908 (2022).
Article CAS PubMed PubMed Central Google Scholar
Leung, C., Rivera, L., Furness, J. B. & Angus, P. W. The role of the gut microbiota in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 13, 412–425 (2016).
Article CAS PubMed Google Scholar
Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 235–246 (2019).
Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 68, 280–295 (2018).
Article CAS PubMed Google Scholar
Park, J. W. et al. Role of microbiota-derived metabolites in alcoholic and non-alcoholic fatty liver diseases. Int. J. Mol. Sci. 23, 426 (2021).
Article PubMed PubMed Central Google Scholar
Kang, Y., Cai, Y. & Yang, Y. The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies. Liver Cancer 11, 113–125 (2022).
Article CAS PubMed Google Scholar
Bence, K. K. & Birnbaum, M. J. Metabolic drivers of non-alcoholic fatty liver disease. Mol. Metab. 50, 101143 (2021).
Article CAS PubMed Google Scholar
Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat. Rev. Neurol. 18, 476–495 (2022).
Doifode, T. et al. The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology. Pharmacol. Res. 164, 105314 (2021).
Article CAS PubMed Google Scholar
Mao, X. Y. et al. Dietary nutrition for neurological disease therapy: Current status and future directions. Pharmacol. Ther. 226, 107861 (2021).
Article CAS PubMed Google Scholar
Yu, Y. & Zhao, F. Microbiota-gut-brain axis in autism spectrum disorder. J. Genet. Genomics 48, 755–762 (2021).
Article CAS PubMed Google Scholar
Honarpisheh, P., Bryan, R. M. & McCullough, L. D. Aging microbiota-gut-brain axis in stroke risk and outcome. Circ. Res. 130, 1112–1144 (2022).
Article CAS PubMed PubMed Central Google Scholar
Simpson, C. A. et al. The gut microbiota in anxiety and depression - A systematic review. Clin. Psychol. Rev. 83, 101943 (2021).
Wang, S. C. et al. Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review. Int J Mol Sci. 21, (2020).
Dai, X. & Wang, B. Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease. Gastroenterol. Res. Pract. 2015, 287348 (2015).
Article PubMed PubMed Central Google Scholar
Wang, P. Y. et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452, 1012–1016 (2008).
Article CAS PubMed Google Scholar
Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 35–56 (2019).
Article CAS PubMed Google Scholar
Muhammad, F. et al. The molecular gut-brain axis in early brain development. Int J Mol Sci 23, 15389 (2022).
Article CAS PubMed PubMed Central Google Scholar
Martin, C. R., Osadchiy, V., Kalani, A. & Mayer, E. A. The brain-gut-microbiome axis. Cell Mol. Gastroenterol. Hepatol. 6, 133–148 (2018).
Article PubMed PubMed Central Google Scholar
Bauer, K. C. et al. Nonalcoholic fatty liver disease and the gut-liver axis: exploring an undernutrition perspective. Gastroenterology 162, 1858–1875.e1852 (2022).
Article CAS PubMed Google Scholar
Bajaj, J. S., Ng, S. C. & Schnabl, B. Promises of microbiome-based therapies. J. Hepatol. 76, 1379–1391 (2022).
Article CAS PubMed PubMed Central Google Scholar
Brescia, P. & Rescigno, M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol. Med. 27, 844–855 (2021).
Article CAS PubMed Google Scholar
Socala, K. et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharm. Res. 172, 105840 (2021).
Thompson, R. J. et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 7, 830–842 (2022).
Zhu, J. H. et al. Efficacy and safety of vibrating capsule for functional constipation (VICONS): a randomised, double-blind, placebo-controlled, multicenter trial. EClinicalMedicine 47, 101407 (2022).
Article PubMed PubMed Central Google Scholar
Wang, X. et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res 29, 787–803 (2019).
Article CAS PubMed PubMed Central Google Scholar
Jena, P. K., Sheng, L., Li, Y. & Wan, Y. Y. Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. Hepatobiliary Surg. Nutr. 9, 170–182 (2020).
Article PubMed PubMed Central Google Scholar
Tan, A. H. et al. Probiotics for constipation in parkinson disease: a randomized placebo-controlled study. Neurology 96, e772–e782 (2021).
Schmidt, K. et al. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology 232, 1793–1801 (2015).
Article CAS PubMed Google Scholar
Huang, H. et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med 12, 102 (2020).
Article CAS PubMed PubMed Central Google Scholar
Marascio, N. et al. The role of the microbiota gut-liver axis during HCV chronic infection: a schematic overview. J Clin Med 11, 5936 (2022).
Article CAS PubMed PubMed Central Google Scholar
Han, H. et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit. Rev. Food Sci. Nutr. 63, 1689–1706 (2023).
Article CAS PubMed Google Scholar
Kong, L. et al. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARalpha to activate the NF-kappaB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance. J. Exp. Clin. Cancer Res. 40, 18 (2021).
Article CAS PubMed PubMed Central Google Scholar
Gong, S. et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J. Hepatol. 69, 51–59 (2018).
Article CAS PubMed PubMed Central Google Scholar
Luo, W. et al. Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front. Microbiol. 13, 873160 (2022).
Comments (0)